Skip to main content
. 2018 Jan 8;9(6):6924–6937. doi: 10.18632/oncotarget.24023

Figure 5.

Figure 5

(A) T47D-Y537S breast cancer cells were treated with increasing doses of ZB716 or fulvestrant for 5 days. At the end of treatment, surviving cells were counted and normalized to control cells that were treated with vehicle (DMSO) only. IC50 values were obtained by deriving logarithmic curves from the %cell survival vs. treatment dose plot. (B) Dose-dependent ER downregulation in T47D/Y537S cells by ZB716 and fulvestrant.